Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Phase 4
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Both
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Trial Information
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Inclusion Criteria
Inclusion criteria:
- gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphoma with Helicobacter
pylori positive
- The stages of MALT lymphoma are Lugano International Conference classification Stage
I or II 1 and Wotherspoon grade 4 or 5
Exclusion criteria:
- With diffuse large B-cell lymphoma
- Have been treated to gastric mucosa-associated lymphoid tissue (MALT) lymphoma
- Corresponding to contraindication of each drug
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori
Outcome Time Frame:
Every 3 months within the 1st year and every 6 months
Safety Issue:
No
Principal Investigator
Katsuya Sugizaki
Investigator Role:
Study Director
Investigator Affiliation:
Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.
Authority:
Japan:Helth, Labour and Welfare Ministry
Study ID:
PRT10T
NCT ID:
NCT01264822
Start Date:
January 2011
Completion Date:
February 2017
Related Keywords:
- Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
- Rabeprazole Sodium
- Helicobacter pylori
- stomach neoplasms
- Lymphoma
- Lymphoma, B-Cell, Marginal Zone
Name | Location |
|---|
